Clinical and molecular findings in a Moroccan family with Jervell and Lange-Nielsen syndrome: a case report

N. Adadi 1,2*, N. Lahrouchi 3, R. Boughouch 4, I. Fellat 4, R. Amri 5, M. Alders 6, A. Sefiani 1,2, C. Bezzina 3 and I. Ratbi 2

Abstract

Background: Jervell and Lange-Nielsen syndrome (Online Mendelian Inheritance in Man 220400) is a rare autosomal recessive cardioauditory ion channel disorder that affects 1/200,000 to 1/1,000,000 children. It is characterized by congenital profound bilateral sensorineural hearing loss, a long QT interval, ventricular tachyarrhythmias, and episodes of torsade de pointes on an electrocardiogram. Cardiac symptoms arise mostly in early childhood and consist of syncopal episodes during periods of stress, exercise, or fright and are associated with a high risk of sudden cardiac death. Jervell and Lange-Nielsen syndrome is caused by homozygous or compound heterozygous mutations in KCNQ1 on 11p15.5 or KCNE1 on 1q22.1-q22.2.

Case presentation: We report the case of a 10-year-old Moroccan boy with congenital hearing loss and severely prolonged QT interval who presented with multiple episodes of syncope. His parents are first-degree cousins. We performed Sanger sequencing and identified a homozygous variant in KCNQ1 (c.1343dupC, p.Glu449Argfs*14).

Conclusions: The identification of the genetic substrate in this patient confirmed the clinical diagnosis of Jervell and Lange-Nielsen syndrome and allowed us to provide him with appropriate management and genetic counseling to his family. In addition, this finding contributes to our understanding of genetic disease in the Moroccan population.

Keywords: Jervell and Lange-Nielsen syndrome, Long QT syndrome, Deafness, Moroccan, Mutation
There was no family history of sudden death, deafness, syncope, epilepsy, or any other genetic disease. The pregnancy had been medically followed, and no complications were reported. His mother presented with no history of drug ingestion or phytotherapy. His birth weight and length were within normal range and no dysmorphic signs were recorded. At 6 months, he was diagnosed as having severe bilateral SNHL on auditory evoked potential measurement. His first syncopal episode occurred at 24 months of age. His ECG revealed a markedly prolonged QTc interval of 530 ms (corrected by Bazett’s formula) and T-wave alternans on V1 to V4 (Fig. 2). Echocardiography showed a structurally normal heart. Treatment was immediately started with a β-adrenergic blocker. His parents and his two younger brothers, who were 7-years old and 1-year old, were clinically normal. Blood samples from all his family’s members were collected after we were given written informed consent. Deoxyribonucleic acid (DNA) was isolated using standard techniques [8]. Molecular genetic testing of the entire coding region and flanking intronic regions of \( KCNQ1 \) and \( KCNE1 \) was undertaken by Sanger sequence analysis (details available on request). This led to

**Fig. 1** Pedigree of the studied family. The affected individual is shaded and indicated by an arrow. Family members that were tested for the mutation are marked by an asterisk

**Fig. 2** Electrocardiogram of the patient
the identification of a homozygous frameshift mutation c.1343dupC (p.Glu449Argfs*14) in the index patient. Both parents and one sibling (IV-2) were heterozygous for this mutation. The youngest child of the family did not carry the frameshift mutation (IV-3, Fig. 3). This variant was previously reported in a heterozygous state in an individual with long QT syndrome (LQTS) [9].

Discussion
The primary electric disorders, which among others include LQTS, short-QT syndrome (SQTS), Brugada syndrome (BrS), and catecholaminergic polymorphic

tachycardia (CPVT), are often characterized by specific ECG abnormalities either at baseline or during particular conditions, such as exercise (for example, CPVT and LQTS), fever (for example, BrS), or pharmacological challenge (for example, BrS). The list of familial arrhythmia syndromes has been in recent years expanded by the recognition of two other disorders, namely early repolarization syndrome and idiopathic ventricular fibrillation (VF) [7].

LQTS is a clinically and genetically heterogeneous disorder. Syncopal episodes may occur from infancy through middle age, with risk of sudden death [10]. The autosomal dominant mode of inheritance is typical for all LQTS forms (previously described as the Romano–Ward syndrome). Three genes account for approximately 90% of patients with genotype-positive LQTS. LQT1 is characterized by broad-based T waves and cardiac events during exercise or emotion. It arises from loss-of-function mutations in KCNQ1. In LQT2, T waves are bifid and cardiac events predominantly occur during exercise or emotion. It arises from loss-of-function mutations in KCNH2 (also known as hERG). Gain-of-function mutations in SCN5A are associated to LQT3. These patients show a long ST segment, short T waves, and experience cardiac events predominantly during rest or sleep. Twelve additional genes encoding either ion channel subunits (KCNJ5, KCNE1, KCNE2, and SCN4B) or proteins that regulate ion channel function (AKAP9, CAV3, ANKB, SNT1, CALM1, and CALM2) have been associated with LQTS; however, most of them are only rarely implicated (<1%) [7].

Jervell and Lange-Nielsen syndrome is a rare clinical variant of LQTS that manifests with extracardiac phenotypes and is inherited in an autosomal recessive fashion. Patients with JLNS present with severe prolongation of the QT interval and congenital SNHL. It is one of the most severe forms of LQTS. By the age of 3 years, 50% of patients have had an event and by the age of 18 years, 90% of patients with JLNS have developed symptoms [2]. Therefore, the real incidence of JLNS is probably underestimated because of its high mortality in early infancy, in particular in populations with a high rate of consanguineous marriages like Morocco [11]. In addition, even in the presence of medical therapy the occurrence of sudden cardiac death in JLNS exceeds 25% [2].

To date, approximately 21 distinct KCNQ1 mutations have been characterized in patients with JLNS according to The Human Gene Mutation Database (HGMD) at the Institute of Medical Genetics in Cardiff (HGMD, http://www.hgmd.cf.ac.uk/ac/index.php). Three different mutations in the KCNE1 gene were also reported in patients with JLNS. These mutations have been found homozygously or in a compound heterozygous state (Fig. 4) and, interestingly, one of the families studied in the initial description of KCNE1 in JLNS originated from Morocco [4].

Fig. 3 Electropherograms of the identified c.1343dupC; p.Glu449Argfs*14 mutation. The proband IV:1 presented with the homozygous c.1343dupC; p.Glu449Argfs*14 mutation and both parents (III:5 and III:6) and unaffected brother IV:2 are heterozygotes. One healthy brother (IV:3) was homozygous for the wild-type allele. The X indicates the position of detected mutation (Duplication of C base). The arrows indicate the location of the mutated base.
In this study, we reported the molecular characterization of a KCNQ1 homozygous frameshift mutation (c.1343dupC) (p.Glu449Argfs*14) in a Moroccan patient with JLNS. This variant was previously identified in a heterozygous state in a 25-month-old girl of Latino origin with severe bilateral SNHL due to a homozygous mutation of connexin 26. She was repeatedly found to have QTc intervals ≥450 ms in a screening program. Sequencing of 12 LQTS genes identified a de novo heterozygous frameshift mutation described in this report (KCNQ1, c.1343dupC; p.Glu449Argfs*14) [9]. To the best of our knowledge, the case of the Moroccan proband reported here is the first case of JLNS carrying this mutation in a homozygous state.

Conclusions

We report here the clinical and molecular description of a Moroccan patient with JLNS. This diagnosis allowed us to provide an appropriate course of management to the patient and to identify and counsel asymptomatic heterozygous carriers.

Acknowledgements

We thank the patient and his family.

Funding

Not applicable.

Availability of data and materials

Available on request.

Authors’ contributions

NA carried out the molecular genetic studies, and drafted the manuscript. NL participated in the clinical diagnosis and helped to draft the manuscript. RB performed clinical examinations and monitoring of the family, IF participated in the clinical diagnosis, MA participated in the sequence alignment, AS participated in the design of the study, CB participated in the design of the study and helped to draft the manuscript, and IR conceived and coordinated the study and helped to draft the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Written informed consent was obtained from the patient’s legal guardian(s) for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal. A consent for publication was obtained from the family. Statements are available on request.

Ethics approval and consent to participate

Ethics approval and consent to participate was provided by all adults and legal guardians of minor individuals involved in this study. Statements of their signed consent are available on request.

This study was approved by the ethics committee of the National Institute of Health in Rabat, Morocco.

Author details

1. Centre de Génomique Humaine, Faculté de Médecine et Pharmacie, Mohammed V University, Rabat, Morocco. 2. Département de Génétique Médicale, Institut National d’Hygiène, Rabat, Morocco. 3. Department of Clinical and Experimental Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands. 4. Electrophysiologie et Stimulation Cardiaque, Clinique Belvédère, Rabat, Morocco. 5. Service de Cardiologie B, CHU Ibn Sina, Rabat, Morocco. 6. Department of Clinical Genetics, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.

Received: 5 October 2016 Accepted: 20 February 2017

Published online: 02 April 2017

References

1. Winbo A, Stattin E, Diamant UB, Persson J, Jensen SM, Rydberg LG. Prevalence, mutation spectrum, and cardiac phenotype of the Jervell and Lange-Nielsen syndrome in Sweden. Europace. 2012;14(12):1799–806.
2. Schwartz PJ, Spazzolini C, Crotti L, Bathen J, Amlie JP, Timothy K, Shkolnikova M, Berul CI, Bitner-Glindzicz M, Toivonen L, et al. The Jervell and Lange-Nielsen syndrome: natural history, molecular basis, and clinical outcome. Circulation. 2006;113(6):783–90.
3. Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the QT interval and sudden death. Am Heart J. 1957;54(1):59–68.
4. Neyroud N, Tesson F, Denjoy I, Leibovici M, Donger C, Barhanin J, Faure S, Gary F, Courmel P, Petit C, et al. A novel mutation in the potassium channel gene KVLQT1 causes the Jervell and Lange-Nielsen cardioauditory syndrome. Nat Genet. 1997;15(2):186–9.
5. Tyson J, Transvaq L, McIntagart M, Larsen LA, Christiansen M, Whiteford ML, Bathen J, Aslaksen B, Solland S, Lund O, et al. The Jervell and Lange-Nielsen cardioauditory syndrome. Nat Genet. 1997;15(2):186–9.
6. Splawski I, Timothy KW, Vincent GM, Atkinson DL, Keating MT. Molecular basis of the long-QT syndrome associated with deafness. N Engl J Med. 1999;336(22):1562–7.
7. Bezzi CR, Lahrouchi N, Priori SG. Genetics of sudden cardiac death. Circ Res. 2015;116(12):1919–36.
8. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215.
9. Chang RK, Lan YT, Silka MJ, Morrow H, Kwong A, Smith-Lang J, Wallerstein R, Lin HJ. Genetic variants for long QT syndrome among infants and children from a statewide newborn hearing screening program cohort. J Pediatr. 2014;164(3):590–5. e591–3.
10. Behere SP, Weindling SN. Inherited arrhythmias: The cardiac channelopathies. Ann Pediatr Cardiol. 2015;8(3):210–20.
11. Jaouad IC, Elalaoui SC, Sbiti A, Elkahf F, Belmahi L, Sefiani A. Consanguineous marriages in Morocco and the consequence for the incidence of autosomal recessive disorders. J Biosoc Sci. 2009;41(5):575–81.